Compare AbbVie Inc (ABBV) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Marriott International Inc — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Marriott International Inc trades at $373.46 (market cap $100.40B). The key difference: AbbVie Inc is far larger — about 4.5× Marriott International Inc 's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MAR | |
|---|---|---|
Market Cap | $449.91B | $100.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $402.54 |
52-Week Low | $184.85 | $255.35 |
Enterprise Value | $513.38B | $117.35B |
Dividend Yield | 2.72% | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Marriott International (MAR) trades at $380.75, up 2.09% today, near its consensus price target of $386.42. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal robust revenue growth to $26.19B in 2025 and a net income margin of 9.72%. Recent developments include a strategic beverage agreement with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook for MAR is positive with analyst consensus leaning bullish (44% Buy ratings), though high debt levels and owner disputes over the Bonvoy loyalty program pose risks. Earnings beats in recent quarters support growth, but valuation metrics like a P/E of 39.76 suggest premium pricing. Investors should weigh solid operational cash flow against escalating liabilities for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
